search
Back to results

A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

Primary Purpose

Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
DCC-3116
Trametinib
Binimetinib
Sotorasib
Sponsored by
Deciphera Pharmaceuticals LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatic Ductal Adenocarcinoma focused on measuring RAF, RAS, KRAS, NRAS, BRAF, DCC-3116, NF1

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female participants ≥18 years of age
  2. Dose Escalation Phase (Part 1):

    1. Participants must have a histologically confirmed diagnosis of an advanced or metastatic solid tumor with a documented RAS, NF1, or RAF mutations.
    2. Progressed despite standard therapies, and received at least 1 prior line of anticancer therapy.

      • Participants with a documented mutation in BRAF V600E or V600K must have received approved treatments known to provide clinical benefit prior to study entry.
    3. Participants enrolled in the DCC-3116 and sotorasib cohort (Cohort D) must have a KRAS G12C mutation.
  3. Dose Expansion Phase (Part 2):

    1. Cohort 1: Patients with Pancreatic Ductal Adenocarcinoma (PDAC).

      • Histologically confirmed PDAC with a documented mutation in KRAS.
      • Received only 1 prior line of systemic therapy in the advanced or metastatic setting.
    2. Cohort 2: Patients with Non-Small Cell Lung Cancer (NSCLC)

      • Histologically confirmed NSCLC with a documented mutation in KRAS, NRAS, NF1, or BRAF.
      • Received at least 2 prior lines but no more than 4 prior lines of systemic therapy in the advanced or metastatic setting.
    3. Cohort 3: Patients with Colorectal Cancer (CRC)

      • Histologically confirmed CRC with a documented mutation in KRAS, NRAS, NF1, or BRAF.
      • Received 2-3 prior lines of systemic therapy in the advanced or metastatic setting.
    4. Cohort 4: Patients with Melanoma

      • Histologically confirmed melanoma with a documented mutation in NRAS.
      • Received 1-2 prior lines of systemic therapy in the advanced or metastatic setting that included T-cell checkpoint inhibitor-based therapy.
      • Have not received prior MEK inhibitor therapy.
    5. Cohort 5: Patients with KRAS G12C mutant NSCLC

      • Histologically confirmed NSCLC with a documented mutation in KRAS G12C.
      • Received at least 1 prior line but no more than 3 prior lines of systemic therapy in the advanced or metastatic setting.
      • Have not received prior sotorasib or other KRAS G12C inhibitor therapy.
  4. Must be able to provide tumor tissue sample
  5. Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 (Dose Escalation) or 0 to 1 (Dose Expansion) at Screening
  6. Adequate organ function and bone marrow function.
  7. If a female of childbearing potential must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements.
  8. Male participants must agree to follow contraception requirements.
  9. Must provide signed consent to participate in the study and is willing to comply with study-specific procedures.

Exclusion Criteria:

  1. Must not have received the following within the specified time periods prior to the first dose of study drug:

    1. Prior therapies (anticancer or therapies given for other reasons) that are known strong or moderate inhibitors or inducers of CYP3A4 or P-gp including certain herbal medications (eg, St. John's Wort): 14 days or 5× the half-life of the medication (whichever is longer)
    2. All other prior anticancer therapies or any therapy that is investigational for the participant's condition with a known safety and PK profile: 14 days or 5× the half-life of the medication (whichever is shorter)
    3. Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug.-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days
    4. Grapefruit or grapefruit juice: 14 days
  2. Have not recovered from all toxicities from prior therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).
  3. Symptomatic central nervous system (CNS) metastases or presence of leptomeningeal disease Note: A participant with previously treated brain metastases may participate provided that they are stable.
  4. New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug.
  5. Prolongation of the QT interval corrected by Fridericia's formula (QTcF) based on repeated demonstration of QTcF >450 ms in males or >470 ms in females at screening, or history of long QT syndrome.
  6. Left ventricular ejection fraction (LVEF) <50% at Screening
  7. Systemic arterial thrombotic or embolic events
  8. Systemic venous thrombotic events
  9. Malabsorption syndrome
  10. Bone disease that requires treatment.
  11. Major surgery within 4 weeks of the first dose of study drug. All surgical wounds must be healed and free of infection or dehiscence before the first dose of the study drug.
  12. Any other clinically significant comorbidities.
  13. For participants receiving DCC-3116 and trametinib combination or DCC-3116 and binimetinib combination: previous treatment with trametinib or binimetinib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to trametinib or binimetinib.
  14. For participants receiving DCC-3116 and sotorasib combination in Dose Escalation Part 1: previous treatment with sotorasib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to sotorasib.
  15. For participants receiving DCC-3116 and sotorasib combination: Use of proton pump inhibitors (PPIs) and H2 receptor antagonists that cannot be discontinued 3 days prior to the start of study drug administration.
  16. Known allergy or hypersensitivity to any component of the investigational drug products.
  17. Known human immunodeficiency virus or hepatitis C infection only if the participant is taking medications that are excluded per protocol, active hepatitis B, or active hepatitis C infection.
  18. If female, the participant is pregnant or lactating.
  19. Ongoing participation in an interventional study.

Sites / Locations

  • Massachusetts General HospitalRecruiting
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone HealthRecruiting
  • Oregon Health and Science UniversityRecruiting
  • Hospital of the University of PennsylvaniaRecruiting
  • NEXT OncologyRecruiting
  • The University of Texas MD Anderson Cancer CenterRecruiting
  • NEXT OncologyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Dose Escalation (Part 1, Cohort A Monotherapy)

Dose Escalation (Part 1, Cohort B Combination)

Dose Escalation (Part 1, Cohort C Combination)

Dose Escalation (Part 1, Cohort D Combination)

Expansion Cohort 1 (Part 2)

Expansion Cohort 2 (Part 2)

Expansion Cohort 3 (Part 2)

Expansion Cohort 4 (Part 2)

Expansion Cohort 5 (Part 2)

Arm Description

DCC-3116 tablets in escalating dose cohorts given orally twice daily (BID) in 28-day cycles as monotherapy (single agent). If no DLT in 3 participants or 1 DLT/6 participants is observed, dose escalation may continue to the next planned dose cohort.

Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with trametinib.

Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with binimetinib.

Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with sotorasib.

DCC-3116 tablets given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) (with a documented mutation in KRAS).

DCC-3116 tablets orally given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with non-small cell lung cancer (NSCLC) (with a documented mutation in KRAS, NRAS, NF1,or BRAF).

DCC-3116 tablets orally given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with colorectal cancer (CRC) (with a documented mutation in KRAS, NRAS, NF1, or BRAF).

DCC-3116 tablets orally given in combination with binimetinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with melanoma (with a documented mutation in NRAS).

DCC-3116 tablets orally given in combination with sotorasib in 28-day cycles to evaluate safety and preliminary efficacy of participants with NSCLC (with a documented mutation in KRAS G12C).

Outcomes

Primary Outcome Measures

Incidence of Adverse Events
Identify the observed adverse events, serious adverse events associated with DCC-3116 as monotherapy and in combination with trametinib, binimetinib, or sotorasib.
Maximum tolerated dose (MTD)
Identify the dose-limiting toxicities for each dose level tested and determine the maximum tolerated dose/recommended Phase 2 doses of DCC-3116 as monotherapy and in combination with trametinib, binimetinib, or sotorasib.
Objective response rate (ORR) (Expansion Phase)
Proportion of participants who achieve CR or PR per RECIST v1.1.

Secondary Outcome Measures

Duration of response (DoR) (Escalation Phase)
DoR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the progressive disease is objectively documented or death, whichever occurs first.
Disease Control Rate (DCR) (Escalation Phase)
The DCR is defined as the proportion of participants who achieve CR, PR, or stable disease [SD] at the specified time point per RECIST v1.1.
Time to response (Escalation Phase)
Time to response is defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per RECIST v1.1.
Progression-free survival (PFS) (Escalation Phase)
PFS is defined as the time from initiation of treatment until documented disease progression per RECIST v1.1 or death, whichever occurs first.
Maximum observed concentration (Cmax)
Measure the maximum observed concentration of DCC-3116 (single-agent and combinations)
Time to maximum observed concentration (Tmax)
Measure the time to maximum plasma concentration of DCC-3116 (single-agent and combinations)
Minimum observed concentration (Cmin)
Measure the minimum observed concentration of DCC-3116 (single-agent and combinations)
Area under the concentration-time curve( AUC)
Measure the AUC of DCC-3116 (single-agent and combinations)

Full Information

First Posted
May 6, 2021
Last Updated
August 2, 2023
Sponsor
Deciphera Pharmaceuticals LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT04892017
Brief Title
A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors
Official Title
A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 15, 2021 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
October 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Deciphera Pharmaceuticals LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma, Advanced Solid Tumor, Metastatic Solid Tumor
Keywords
RAF, RAS, KRAS, NRAS, BRAF, DCC-3116, NF1

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
323 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dose Escalation (Part 1, Cohort A Monotherapy)
Arm Type
Experimental
Arm Description
DCC-3116 tablets in escalating dose cohorts given orally twice daily (BID) in 28-day cycles as monotherapy (single agent). If no DLT in 3 participants or 1 DLT/6 participants is observed, dose escalation may continue to the next planned dose cohort.
Arm Title
Dose Escalation (Part 1, Cohort B Combination)
Arm Type
Experimental
Arm Description
Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with trametinib.
Arm Title
Dose Escalation (Part 1, Cohort C Combination)
Arm Type
Experimental
Arm Description
Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with binimetinib.
Arm Title
Dose Escalation (Part 1, Cohort D Combination)
Arm Type
Experimental
Arm Description
Upon determination of the RP2D/MTD single agent, DCC-3116 will be dosed in combination with sotorasib.
Arm Title
Expansion Cohort 1 (Part 2)
Arm Type
Experimental
Arm Description
DCC-3116 tablets given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) (with a documented mutation in KRAS).
Arm Title
Expansion Cohort 2 (Part 2)
Arm Type
Experimental
Arm Description
DCC-3116 tablets orally given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with non-small cell lung cancer (NSCLC) (with a documented mutation in KRAS, NRAS, NF1,or BRAF).
Arm Title
Expansion Cohort 3 (Part 2)
Arm Type
Experimental
Arm Description
DCC-3116 tablets orally given in combination with trametinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with colorectal cancer (CRC) (with a documented mutation in KRAS, NRAS, NF1, or BRAF).
Arm Title
Expansion Cohort 4 (Part 2)
Arm Type
Experimental
Arm Description
DCC-3116 tablets orally given in combination with binimetinib in 28-day cycles to evaluate safety and preliminary efficacy of participants with melanoma (with a documented mutation in NRAS).
Arm Title
Expansion Cohort 5 (Part 2)
Arm Type
Experimental
Arm Description
DCC-3116 tablets orally given in combination with sotorasib in 28-day cycles to evaluate safety and preliminary efficacy of participants with NSCLC (with a documented mutation in KRAS G12C).
Intervention Type
Drug
Intervention Name(s)
DCC-3116
Intervention Description
Oral Tablet Formulation
Intervention Type
Drug
Intervention Name(s)
Trametinib
Intervention Description
Oral Tablet Formulation
Intervention Type
Drug
Intervention Name(s)
Binimetinib
Intervention Description
Oral Tablet Formulation
Intervention Type
Drug
Intervention Name(s)
Sotorasib
Intervention Description
Oral Tablet Formulation
Primary Outcome Measure Information:
Title
Incidence of Adverse Events
Description
Identify the observed adverse events, serious adverse events associated with DCC-3116 as monotherapy and in combination with trametinib, binimetinib, or sotorasib.
Time Frame
Approximately 24 months
Title
Maximum tolerated dose (MTD)
Description
Identify the dose-limiting toxicities for each dose level tested and determine the maximum tolerated dose/recommended Phase 2 doses of DCC-3116 as monotherapy and in combination with trametinib, binimetinib, or sotorasib.
Time Frame
Approximately 18 months
Title
Objective response rate (ORR) (Expansion Phase)
Description
Proportion of participants who achieve CR or PR per RECIST v1.1.
Time Frame
Approximately 24 months
Secondary Outcome Measure Information:
Title
Duration of response (DoR) (Escalation Phase)
Description
DoR is defined as the time interval from the time that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the progressive disease is objectively documented or death, whichever occurs first.
Time Frame
Approximately 24 months
Title
Disease Control Rate (DCR) (Escalation Phase)
Description
The DCR is defined as the proportion of participants who achieve CR, PR, or stable disease [SD] at the specified time point per RECIST v1.1.
Time Frame
Approximately 24 months
Title
Time to response (Escalation Phase)
Description
Time to response is defined as the time from initiation of treatment until the first assessment demonstrating CR or PR per RECIST v1.1.
Time Frame
Approximately 24 months
Title
Progression-free survival (PFS) (Escalation Phase)
Description
PFS is defined as the time from initiation of treatment until documented disease progression per RECIST v1.1 or death, whichever occurs first.
Time Frame
Approximately 24 months
Title
Maximum observed concentration (Cmax)
Description
Measure the maximum observed concentration of DCC-3116 (single-agent and combinations)
Time Frame
Predose and up to 12 hours postdose.
Title
Time to maximum observed concentration (Tmax)
Description
Measure the time to maximum plasma concentration of DCC-3116 (single-agent and combinations)
Time Frame
Predose and up to 12 hours postdose.
Title
Minimum observed concentration (Cmin)
Description
Measure the minimum observed concentration of DCC-3116 (single-agent and combinations)
Time Frame
Predose and up to 12 hours postdose.
Title
Area under the concentration-time curve( AUC)
Description
Measure the AUC of DCC-3116 (single-agent and combinations)
Time Frame
Predose and up to 12 hours postdose.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female participants ≥18 years of age Dose Escalation Phase (Part 1): Participants must have a pathologically confirmed diagnosis of an advanced or metastatic solid tumor with a documented RAS, NF1, or RAF mutations. A molecular pathology report documenting mutational status of RAS, NF1, or RAF must be available. Progressed despite standard therapies, and received at least 1 prior line of anticancer therapy. Participants with a documented mutation in BRAF V600E or V600K must have received approved treatments known to provide clinical benefit prior to study entry. Participants enrolled in the DCC-3116 and sotorasib cohort (Cohort D) must have a KRAS G12C mutation. Dose Expansion Phase (Part 2): Cohort 1: Patients with Pancreatic Ductal Adenocarcinoma (PDAC). Pathologically confirmed PDAC with a documented mutation in KRAS. Received only 1 prior line of systemic therapy in the advanced or metastatic setting. Cohort 2: Patients with Non-Small Cell Lung Cancer (NSCLC) Pathologically confirmed NSCLC with a documented mutation in KRAS, NRAS, NF1, or BRAF. Received at least 2 prior lines but no more than 4 prior lines of systemic therapy in the advanced or metastatic setting. Cohort 3: Patients with Colorectal Cancer (CRC) Pathologically confirmed CRC with a documented mutation in KRAS, NRAS, NF1, or BRAF. Received at least 2 prior lines of systemic therapy in the advanced or metastatic setting. Cohort 4: Patients with Melanoma Pathologically confirmed melanoma with a documented mutation in NRAS. Received at least 1 but not more than 2 prior lines of systemic therapy in the advanced or metastatic setting that included T-cell checkpoint inhibitor-based therapy. Have not received prior MEK inhibitor therapy. Cohort 5: Patients with KRAS G12C mutant NSCLC Pathologically confirmed NSCLC with a documented mutation in KRAS G12C. Received at least 1 prior line but no more than 3 prior lines of systemic therapy in the advanced or metastatic setting. Have not received prior sotorasib or other KRAS G12C inhibitor therapy. Must provide a fresh tumor biopsy from a primary or metastatic cancer lesion that can be biopsied with acceptable risk as determined by the Investigator, and an archival tumor tissue sample, if available. If a fresh tumor biopsy is not possible, then an archival tumor tissue sample must be provided. Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 (Dose Escalation) or 0 to 1 (Dose Expansion) at Screening Adequate organ function and bone marrow function. If a female of childbearing potential must have a negative pregnancy test prior to enrollment and agree to follow the contraception requirements. Male participants must agree to follow contraception requirements. Must provide signed consent to participate in the study and is willing to comply with study-specific procedures. Exclusion Criteria: Must not have received the following within the specified time periods prior to the first dose of study drug: Prior therapies (anticancer or therapies given for other reasons) that are known strong or moderate inhibitors or inducers of CYP3A4 or P-gp including certain herbal medications (eg, St. John's Wort): 14 days or 5× the half-life of the medication (whichever is longer) All other prior anticancer therapies or any therapy that is investigational for the participant's condition with a known safety and PK profile: 14 days or 5× the half-life of the medication (whichever is shorter) Investigational therapies with unknown safety and PK profile: 28 days. If there is enough data on the investigational therapy to assess the risk for drug.-drug interactions and late toxicities of prior therapy as low, the Sponsor's Medical Monitor may approve a shorter washout of 14 days Grapefruit or grapefruit juice: 14 days Have not recovered from all toxicities from prior therapy according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Presence or history of central nervous system (CNS) metastases or leptomeningeal disease, with some exceptions New York Heart Association Class III or IV heart disease, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, congestive heart failure, or myocardial infarction within 6 months prior to the first dose of study drug. Prolongation of the QT interval corrected by Fridericia's formula (QTcF) based on repeated demonstration of QTcF >450 ms in males or >470 ms in females at screening, or history of long QT syndrome. Left ventricular ejection fraction (LVEF) <50% at Screening Systemic arterial thrombotic or embolic events Systemic venous thrombotic events Malabsorption syndrome Bone disease that requires ongoing treatment or has required treatment. Major surgery within 4 weeks of the first dose of study drug. All surgical wounds must be healed and free of infection or dehiscence before the first dose of the study drug. Any other clinically significant comorbidities. For participants receiving DCC-3116 and trametinib combination or DCC-3116 and binimetinib combination: previous treatment with trametinib or binimetinib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to trametinib or binimetinib. For participants receiving DCC-3116 and sotorasib combination in Dose Escalation Part 1: previous treatment with sotorasib that resulted in treatment discontinuation due to intolerability as a result of an adverse event (AE) that was considered related to sotorasib. For participants receiving DCC-3116 and sotorasib combination: Use of proton pump inhibitors (PPIs) and H2 receptor antagonists that cannot be discontinued 3 days prior to the start of study drug administration. Known allergy or hypersensitivity to any component of the investigational drug products. Known human immunodeficiency virus unless the following requirements are met: CD4 count >350/µL No AIDS-defining opportunistic infection in the last 12 months Stable anti-retroviral regimen with medications that are not prohibited by the protocol for at least 4 weeks with HIV viral load less than 400 copies/mL prior to enrollment. Known active hepatitis B, active hepatitis C infection or if the participant is taking medications that are prohibited per protocol. If female, the participant is pregnant or lactating. Ongoing participation in an interventional study. For participants receiving DCC-3116 and binimetinib combination: Known Gilbert's syndrome
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Clinical Team
Phone
833-432-2237
Email
clinicaltrials@deciphera.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Team
Organizational Affiliation
Deciphera Pharmaceuticals LLC
Official's Role
Study Director
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Colin Weekes, MD, PhD
Phone
617-726-4000
Email
cdweekes@mgh.harvard.edu
Facility Name
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Janice Mehnert, MD
Phone
212-731-5431
Email
janice.mehnert@nyulangone.org
Facility Name
Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurie Oliveira
Phone
503-418-9628
Email
oliveirl@ohsu.edu
First Name & Middle Initial & Last Name & Degree
Vicki Abtin
Phone
5034946542
Email
abtin@ohsu.edu
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ravi Amaravadi, MD
Phone
215-796-5159
Email
ravi.amaravadi@uphs.upenn.edu
Facility Name
NEXT Oncology
City
Austin
State/Province
Texas
ZIP/Postal Code
78758
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Andrae Vandross
Phone
737-610-5200
Email
avandross@nextoncology.com
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ly Nguyen
Phone
713-563-2169
Email
LMNguyen1@mdanderson.org
Facility Name
NEXT Oncology
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cheryl Merendon
Phone
210-580-9500
Email
cmerendon@nextoncology.com

12. IPD Sharing Statement

Learn more about this trial

A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors

We'll reach out to this number within 24 hrs